Overview of the African Network for Drugs and Diagnostics Innovation (ANDI)

Transcription

1 Overview of the African Network for Drugs and Diagnostics Innovation (ANDI) Dr Sanaa Botros Theodor Bilharz Research Institute, Cairo Egypt and Dr Solomon Nwaka WHO-TDR on behalf of the ANDI Task Force

2 Major recommendations and strategies 2001 Macroeconomics and Health report 2008 Global Strategy and Plan of Action (GSPA) Key recommendations for local ownership Declaration of the Decade of African Traditional Medicine 2005 UN Millennium Project G8 Gleneagles Bamako call for action 2009 WHA62 G8 L'Aquila Algiers declaration Key ANDI events st ANDI stakeholder meeting (Abuja, Nigeria) 2009 WHA62 support 1 st & 2 nd ANDI Task force meetings 2 nd ANDI stakeholder meeting Implementation of ANDI Note: Not drawn to scale SOURCE: Institutional reports, institutional web pages, Mboya-Okeyo, Ridley & Nwaka (Lancet, 2009) 1

3 Strategic business plan adopted 2

4 Unmet health needs in Africa despite ongoing efforts 2006 Life expectancy (years) With 15% of global population, Africa accounts for 25% of global disease burden in DALYs 1/3 of Africans below poverty line Several highly prevalent diseases currently unaddressed by drugs or diagnostics Europe 1,000 3,500 10,000 35,000 GDP/capita (log of int. USD 1 ) Africa Americas Oceania Asia 1 Logarithm in base 10 of current international dollars; Purchasing power parity (PPP)-adjusted figures SOURCE: UN 3

5 To understand the African R&D landscape, a multitude of stakeholders and sources tapped Country visits Interviews outside of Africa Data sources Interviews in Africa South Africa Nigeria Egypt Kenya Burkina Faso Group interviews 1-on-1 interviews Phone interviews > 30,000 papers analyzed > 1,500 clinical trials analyzed > 160 African patents analyzed > 120 pharmaceutical companies surveyed 1-on-1 interviews Focus groups Plenary sessions Note: sources consulted included databases, institutional web pages and reports (foundations, PPPs, pharma companies) SOURCE: Country visits, interviews 4

6 Series of challenges in the African R&D landscape emerged 1 Research gap Little or no clinical trials for several African diseases (e.g. HAT, Lymph Filariasis) Reduced research output for these diseases 2 Little intra African collaboration Less than 5% of published articles involve more than one African countries 3 Significant investment gap Africa invests less than 50% of world medium on R&D Gap on drug/diagnostic innovation estimated at USD billion/year 5

7 HIV/AIDS research Size equivalent to no. of article with lead author Univ Washington London Sch Hyg & Trop Med Univ Alabama Univ London CDC Univ North Carolina Johns Hopkins Univ Columbia Univ Univ Oxford Harvard Univ Institut Pasteur WHO UCL Univ Amsterdam UCSF Makerere Univ Univ Nairobi Muhimbili Univ Univ Zimbabwe Univ Witwatersrand Natl Inst Communicable Dis Univ KwaZulu Univ Cape Town SOURCE: Thomson Web of Science, UCINET 6

8 Significant R&D investment gap, with Africa investing less than 50% of the world median R&D spending per capita USD PPP 1, p.a Total gap of USD 14.3 billion p.a. Of which up to USD 2.4 billion for drugs/ diagnostics innovation World Median 25 GDP share (Percent) N. Amer W. Eu Japan Singa H. Kong Korea Other Asia 2 E. Eu S. Amer SE Asia Africa 1 Countries mean of 2002 data in international dollars at purchasing power parity (PPP) 2 Middle East and East Asia; excludes China (49.8 USD; 1% of GDP) SOURCE: UNDP, World Bank 7

9 Mapping of African research output reveals that several "hot spots" or competency centers exist today Rabat Casablanca Marrakech Morocco Algeria Algiers Tunisia Tunis Monastir Sousse Sfax Libya Alexandria Cairo Tanta Egypt Assiat Senegal Dakar Gambia Cape Verde No of articles < >=1,000 Mauritania Mali Burkina Benin Nigeria Zaria Abidjan Ibadan Lagos Enuga Cameroon Accra Part Harcourt Ivory Ghana Yaounde Coast Equatorial Guinea Gabon Niger Congo South Africa Chad Angola Namibia Rwanda Burundi Zambia Botswana Johannesburg Potchefstroom Sudan Pretoria Uganda Kampala Khartoum Tanzania Zimbabwe Ethiopia Kenya Swaziland Pietermaritzburg Durban Bloemfonteem Addis Ababa Nairobi Morogoro Eritrea Djibouti Dar es salaam Somalia Seychelles Madagascar Cities with 30 or more articles published in the period Total of 90 cities in 27 countries 16,647 biomedical articles led by African authors included in analysis Note: Only top 40 cities by research output labeled Cape Town SOURCE: Thomson Web of Science 8

10 In addition, some African centers show patent activity in the biomedical areas Canada Belgium Netherlands UK US France Japan Patent # Morocco Guinea Tunisia Egypt Benin Kenya Madagascar > 11 Uruguay South Africa Total: 164 Note: Patents published in the period by WIPO or the US and European patent offices with at least one assignee from Africa (under under International Patent Codes A61K or A61P) SOURCE: Delphion, VantagePoint, UCINET 9

11 ANDI s Mission and Vision seeks to overcome challenges Mission Statement "To promote and sustain African-led health product innovation to address African public health needs through assembly of research networks, and building of capacity to support human and economic development" Vision "Creating a sustainable platform for R&D innovation in Africa to address Africa s own health needs" 10

12 The proposed business model of ANDI Scope Function Core R&D activities Network support Brokerage Project/portfolio management Funding IP management Research equipment Research facilities Knowledge/IT management Advocacy Public/private partnerships Project 1 Project 2 Project 3 Example: Drug for TB/Malaria Example: Schisto diagnostic Competence/excellence centers developed R&D capability built Infrastructure improved Example: TM 1 project 1 TM, Traditional Medicine SOURCE: Abuja meeting, Country visits, interviews, Task Force meetings 11

13 BUSINESS MODEL ANDI is unique, compared to other initiatives African-led Projects driven by local investigators African-oriented with agenda aligned with local priorities Sustainability Focus on: Creating a backbone for product innovation, adapted to evolving health needs Moving products along the R&D value chain African & external interface Partner for other organizations operating in Africa, in line with the GSPA 12

14 Organization and governance structure - Board and Secretariat Board Board Executive committee (EC) Finance Committee (FC) Overview Long-term strategy setting Determining scientific focus Oversight of Executive Director (ED) Oversight (via EC) of ANDI's office Oversight (via FC) of budget and accountability/sustainability of African Innovation Fund STAC ANDI Office Advocacy IP/technology transfer R&D coordination African Innovation Fund Key facts Reflection of ANDI's stakeholders and needs Diaspora African researchers Chair Vice-Chair AfDB ED North hub West hub Central hub South hub East hub UN-based organizations NGO Private sector ~ 70% are African members STAC Chair African regions Observers OECD 13

15 ANDI's Approach to IP Need for IP management identified in R&D landscape mapping activity WIPO working with ANDI task force to develop IP strategy (cf SBP) Possible areas of support identified: Assistance on IP management for projects incl preparation of MTA, CDA and collaborative agreements Training on IP management (workshops, etc) Regular mapping of R&D landscape in Africa Design of a network IP policy 14

16 Annual budget ~USD 31 M by 2015 for 15 network projects Total cost (USD million) ANDI projects (Number) Local contribution (USD million) Project funding (Percent of total) Total ANDI cost ANDI project costs ANDI running costs Year Including one-off costs 15

17 Implementation of ANDI interim & definitive hosting plan Status Provisional management by WHO/TDR At African hosts Key steps Board formation Location selection Staffing Full operation in Africa Legal status Project at TDR Legal entity at AfDB In addition Ad-interim team Start Board formation Prepare 1 st project calls Board appointed Legal agreements Start ED selection Project selection and preparation ED appointed Full team appointed Project portfolio fully up and running Support platforms up and running 16